← Leaderboards
Mark Gelfand
Coridea, Llc
$3,148,107
Attributed
$3,148,107
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $988.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,148,107 · 2
By mechanism
R44$3,148,107 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Life”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Martha Hering · Westat, Inc.$57,098,843
Research focus
LifeOperative Surgical ProceduresHistopathologyLeadMeetingsNext GenerationFatigueHealingImplantInnovationDiagnosisAcuteMinimally InvasiveMortalityDevicesBiomaterial CompatibilityGrantChronicDesignHourCustomImplantationAnimalsPerformance
Grant awards (5)
ENT-based Approach to Cervical Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea$982,086
R44 · FY2025 · HL · contact PI
Endobronchial Supervalve for the Treatment of Emphysema$988,194
R44 · FY2022 · HL · contact PI
Endobronchial Supervalve for the Treatment of Emphysema$805,212
R44 · FY2021 · HL · contact PI
Endobronchial Supervalve for the Treatment of Emphysema$126,200
R44 · FY2021 · HL · contact PI
Endobronchial Supervalve for the Treatment of Emphysema$246,415
R44 · FY2020 · HL · contact PI